Targets to treat metabolic syndrome in polycystic ovary syndrome
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Metabolic syndrome is comprised of a combination of the following states: increased insulin resistance, dyslipidemia, cardiovascular disease, and increased abdominal obesity. Women with polycystic ovary syndrome (PCOS) have an increased risk of developing metabolic syndrome over the course of their lives. Metabolic syndrome increases risk of major cardiovascular events, morbidity, quality of life, and overall health care costs. Though metabolic syndrome in women with PCOS is an area of great concern, there is no effective individual medical therapeutic to adequately treat this issue. AREAS COVERED: This article will review key aspects of metabolic syndrome in PCOS. We will discuss classic and novel therapeutics to address metabolic syndrome in women with PCOS. We will conclude with the importance of developing strategic interventions to increase the compliance to lifestyle and dietary modification, in addition to appreciation of the emerging pharmaceutical therapeutics available. EXPERT OPINION: Innovation in lifestyle modification, including diet, exercise, with and without dedicated stress reduction techniques is the future in treatment of metabolic syndrome in PCOS. Application of novel interventions, such as group medical care, may improve future adherence to lifestyle modification recommendations, in addition to or in combination with pharmaceutical therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143
Self-citationDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 2×
“Insulin resistance has been demonstrated in many target tissues such as skeletal muscle, fibroblasts and adipose tissue with abnormalities suggested in insulin receptors and post-receptor signaling.[80,81] Counter to the insulin resistance noted in peripheral tissues, ovarian insulin responsiveness has remained intact…”
BackgroundSelf-citationYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
March, W. A., Moore, V. M., Willson, K. J., Phillips, D. I. W., Norman, R. J., & Davies, M. J. (2010) · Human Reproduction · doi:10.1093/humrep/dep399 · Cited by 1,799
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Teede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565
Effects of the amount and intensity of exercise on plasma lipoproteins
Kraus, W. E., Houmard, J. A., Duscha, B. D., Knetzger, K. J., Wharton, M. B., McCartney, J. S., Bales, C. W., Henes, S., Samsa, G. P., Otvos, J. D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020194 · Cited by 1,554 · cited 1×
“Dyslipidemia Abnormalities in lipid metabolism and fasting lipid profiles in women with PCOS are variable and are due to a combination of insulin resistance,[93] obesity,[94] with additional modification by diet,[95–97] amount of exercise[98] and genetic predisposition.”
BackgroundIncreasing Prevalence of the Metabolic Syndrome Among U.S. Adults
Ford, E. S., Giles, W. H., & Mokdad, A. H. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2444 · Cited by 1,488
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 21×
“These findings highlight the presence of glucose intolerance and type 2 diabetes mellitus in nonobese and young women with PCOS.”
BackgroundInfluentialMoran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108
Cited by
Polycystic ovary syndrome and mitochondrial dysfunction
Zhang, J., Bao, Y., Zhou, X., & Zheng, L. (2019) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-019-0509-4 · Cited by 258
Tabassum, F., Jyoti, C., Sinha, H. H., Dhar, K., & Akhtar, M. S. (2021) · PLOS ONE · doi:10.1371/journal.pone.0247486 · Cited by 94
“However, novel treatments and therapies can then be targeted toward improving those problems, which are most important for the individual concerned [13,14].”
BackgroundPrenatal Exposure to Endocrine Disruptors: A Developmental Etiology for Polycystic Ovary Syndrome
Hewlett, M., Chow, E., Aschengrau, A., & Mahalingaiah, S. (2017) · Reproductive Sciences · doi:10.1177/1933719116654992 · Cited by 61
Self-citationTosatti, J. A. G., Alves, M. T., Cândido, A. L., Reis, F. M., Araújo, V. E., & Gomes, K. B. (2021) · British Journal of Nutrition · doi:10.1017/s0007114520003207 · Cited by 38
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00942-2 · Cited by 25
Metadata
- Authors
- Mahalingaiah, S., & Diamanti-Kandarakis, E.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2015-10-21
- Volume
- 19
- Issue
- 11
- Pages
- 1561-1574
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2116254170
- Cited by
- 43
- References
- 35
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targets to treat metabolic syndrome in polycystic ovary syndrome. https://app.cochat.ai/papers/10.1517/14728222.2015.1101067
- The paper
- Mahalingaiah, S., & Diamanti-Kandarakis, E. (2015). Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2015.1101067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.